NCT00828828

Antibody Response to Influenza Vaccine in Patients With Sarcoidosis

Controlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With Sarcoidosis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 49 (actual)
• Sponsor: Shahid Beheshti University of Medical Sciences · Academic / Other
• Sex: All
• Age: 20 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the efficacy of influenza vaccine (antibody response) in patients with sarcoidosis.

Detailed description

Sarcoidosis is a multisystem disease with unclear etiology characterized by the presence of noncaseating granuloma\[1\]. T helper cells response is exaggerated at the site of disease and cellular immunity depressed in peripheral blood\[2\]. Cutaneous anergy, lymphopenia and inversion of CD4/CD8 ratio in peripheral blood suggest T helper cells involvement\[3\]. The action of humeral immune system in sarcoidosis is a matter of controversy. Standard hepatitis B virus vaccination did not provoke protective antibody titer in patients with sarcoidosis\[3\]. Although antibody response against influenza vaccine in patients with sarcoidosis is not well described, this vaccine is highly recommended in patients with chronic pulmonary diseases such as asthma, COPD and fibrosis \[4, 5, 6\]. In this study we aim to evaluate the humeral response to the influenza vaccine in sarcoidosis patients and assess vaccine safety.

Conditions

• Pulmonary Sarcoidosis

Interventions

Type	Name	Description
BIOLOGICAL	Influenza Vaccine	One 0.5 ml dose of influenza vaccine injected intramuscular.

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-02-01
• Completion: 2009-05-01
• First posted: 2009-01-26
• Last updated: 2009-05-21

Locations

1 site across 1 country: Iran